Recent news

Archived news

We have been informed by Chineese Patent Office that our patent application no 201580028495.1, concerning our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and environmental processes is being processed. We are awaiting for further decisions.

Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and environmental processes has been granted with United States patent. We are awaiting for issuing the patent number (the application number 2017/0095553 A1).



Scientific publication in the area of industrial enzymes. A novel proteinase Onygena, an improved alternative to the ‘workhorse’ of molecular biology – proteinase K has been cloned, expressed and characterised as a result of cooperation with Barentzymes AS, a Norwegian biotechnology company (part of Fluenta holding). The results have been published in high rank journal Microbial Cell Factories (IF = 4.6) and protected by EU patent application. The Onygena proteinase is more active and works at lower temperaturę tan proteinase K, thus is uniquelly suited as an enzymatic tools for waste utilization, environment pollution control, protein sequencing, removal and analysis (Microb Cell Fact (2020) 19:135).


An alternative for proteinase K‑heat‑sen
.
Download • 1.90MB